Developer docs
API playgroundTry for free, no card

Search company profiles

Enspectra Health

Full company profile

uuid0000eot

Namestring
Enspectra Health
Legal namestring
Enspectra Health, Inc.
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-invasive skin imaging, dermatology medical devices, virtual biopsy technology, multiphoton laser imaging, AI dermatology diagnostics
Industry1 code
PRIMARYHDAAAEAH
Medical Imaging AI
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Dermatology medical imaging devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

Sale of VIO imaging hardware system to dermatologists and healthcare providers for point-of-care skin assessments

enspectrahealth.com
2Software/Subscription Services
TypeSubscription Recurring
Description

AI-powered insights and analysis capabilities bundled with the device for real-time dermatological assessments

enspectrahealth.com
3Service and Support
TypeProfessional Services
Description

Ongoing maintenance, support, and potentially consumables associated with the imaging device

enspectrahealth.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Enspectra Health develops and sells the VIO™ imaging system, a handheld medical device that combines multiphoton laser scanning with reflectance confocal microscopy to deliver non-invasive, real-time high-resolution digital images of live skin cells. The device is FDA-cleared and accompanied by AI-powered analysis that enables dermatologists to perform "virtual biopsies" for evaluating conditions such as nonmelanoma skin cancers without surgical incisions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Validated in VISTA Trial published in JAMA Dermatology showing high accuracy for noninvasive identification of key skin features
+2 more records
Product overview1 text field

Enspectra Health offers a single unified product—the VIO™ imaging system—which combines multiphoton laser scanning with reflectance confocal microscopy in a handheld device. The VIO system enables clinicians to perform virtual biopsies, generating high-resolution digital images of live cells without incisions and providing AI-powered insights for dermatological assessments. The technology has received FDA clearance for clinical use in evaluating skin conditions including nonmelanoma skin cancers.

Product and service1 record
1VIO™ Imaging System
CategoryDermatology medical imaging device
Description

A handheld skin imaging system that combines multiphoton laser scanning with reflectance confocal microscopy to deliver actionable cellular information noninvasively in real time. It enables dermatologists to perform "virtual biopsies" for evaluating nonmelanoma skin cancers and broader skin conditions without surgical incisions, and is paired with AI-powered analysis to support point-of-care decision-making. Intended for dermatologists, dermatology practices, hospitals, and healthcare systems.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

University of California San Francisco partnership for research and clinical development of the imaging technology

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Stanford University partnership for clinical research and technology development

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major healthcare system partnership for clinical validation and research collaboration

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Caliber I&D manufactures the VivaScope, a reflectance confocal microscopy system for non-invasive skin imaging. It is the closest direct competitor to Enspectra's VIO system, as both aim to provide non-invasive cellular-level visualization of skin at the point of care.

TypeDirect peer
Description

Michelson Diagnostics offers the VivoSight optical coherence tomography + confocal system for dermatology imaging. It competes directly with Enspectra in non-invasive skin imaging for lesion evaluation and shares the same enterprise dermatology customer base.

TypeBroad incumbent
Description

Canfield Scientific is the leading dermatology imaging vendor (VECTRA, IntelliStudio, VISIA) used by dermatologists and plastic surgeons for total body photography and lesion documentation. It is a broad incumbent in dermatology imaging workflows that Enspectra must integrate alongside or displace.

TypeBroad incumbent
Description

FotoFinder provides AI-assisted total body dermatoscopy and mole mapping systems widely used by dermatology practices globally. As a broad incumbent in dermatology imaging with AI, it represents the established workflow that Enspectra's point-of-care cellular imaging would complement or compete with.

TypeDirect peer
Description

MetaOptima's DermEngine is an AI-powered dermatoscopy and tele-dermatology platform used by dermatologists for lesion tracking and AI-assisted assessment. It directly overlaps with Enspectra's AI-powered skin health assessment value proposition and target buyer.

TypeEmerging player
Description

Skin Analytics is an emerging AI dermatology company (DERM) with regulatory clearances for autonomous skin cancer triage in the UK and EU. It competes in the same AI dermatology triage market as Enspectra but is currently focused on teledermatology and primary care pathways.

TypeEmerging player
Description

SkinVision offers a smartphone-based AI app for skin lesion risk assessment with regulatory clearances in Europe. It is an emerging player in AI dermatology triage and overlaps with Enspectra's thesis that non-invasive AI tools can reduce unnecessary biopsies.

TypeBroad incumbent
Description

Verily, an Alphabet health-tech company, has invested in dermatology AI and clinical research tools through partnerships and internal programs. As a broad incumbent with deep capital and data resources, it represents a well-capitalized competitive threat in AI dermatology.

TypeBroad incumbent
Description

STRATA Skin Sciences markets dermatology imaging and diagnostic systems to dermatology practices. As a public dermatology imaging incumbent, it represents an established commercial channel and a potential acquirer or competitor for Enspectra's VIO technology.

103Gen (DermLite)
TypeBroad incumbent
Description

DermLite is a market-leading manufacturer of handheld dermatoscopes used in nearly every dermatology practice. It is a broad incumbent in the point-of-care skin imaging workflow that Enspectra is targeting with its VIO handheld form factor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enspectra Health

Dermatology medical imaging devicesenspectrahealth.com

Enspectra Health firmographics

Firmographics
Name
Enspectra Health
Legal name
Enspectra Health, Inc.
Website
https://enspectrahealth.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Enspectra Health industry classification

Industry
Product category
Dermatology medical imaging devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI

Keywords

  • Non-invasive skin imaging
  • Dermatology medical devices
  • Virtual biopsy technology
  • Multiphoton laser imaging
  • AI dermatology diagnostics

Where Enspectra Health is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Enspectra Health business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Sales: Sale of VIO imaging hardware system to dermatologists and healthcare providers for point-of-care skin assessments
  2. Software/Subscription Services: AI-powered insights and analysis capabilities bundled with the device for real-time dermatological assessments
  3. Service and Support: Ongoing maintenance, support, and potentially consumables associated with the imaging device

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Enspectra Health product offering

Product offering

Core offering

Enspectra Health develops and sells the VIO™ imaging system, a handheld medical device that combines multiphoton laser scanning with reflectance confocal microscopy to deliver non-invasive, real-time high-resolution digital images of live skin cells. The device is FDA-cleared and accompanied by AI-powered analysis that enables dermatologists to perform "virtual biopsies" for evaluating conditions such as nonmelanoma skin cancers without surgical incisions.

Product overview

Enspectra Health offers a single unified product—the VIO™ imaging system—which combines multiphoton laser scanning with reflectance confocal microscopy in a handheld device. The VIO system enables clinicians to perform virtual biopsies, generating high-resolution digital images of live cells without incisions and providing AI-powered insights for dermatological assessments. The technology has received FDA clearance for clinical use in evaluating skin conditions including nonmelanoma skin cancers.

Differentiator

Problem solved

Functional benefit

Products and services

  • VIO™ Imaging System A handheld skin imaging system that combines multiphoton laser scanning with reflectance confocal microscopy to deliver actionable cellular information noninvasively in real time. It enables dermatologists to perform "virtual biopsies" for evaluating nonmelanoma skin cancers and broader skin conditions without surgical incisions, and is paired with AI-powered analysis to support point-of-care decision-making. Intended for dermatologists, dermatology practices, hospitals, and healthcare systems.

Quantifiable outcome

  • Validated in VISTA Trial published in JAMA Dermatology showing high accuracy for noninvasive identification of key skin features
  • +2 more outcomes

Companies that use Enspectra Health

Customer profile

Segments3 records

Ideal customer profiles3 records

Enspectra Health technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Enspectra Health partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • UCSFcoreStrategic or Co-development PartnerUniversity of California San Francisco partnership for research and clinical development of the imaging technology
  • StanfordcoreStrategic or Co-development PartnerStanford University partnership for clinical research and technology development
  • Mass General BrighamcoreStrategic or Co-development PartnerMajor healthcare system partnership for clinical validation and research collaboration

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Enspectra Health competitors and assessment

Company assessment

Direct peers

  • Caliber Imaging & Diagnostics (VivaScope): Caliber I&D manufactures the VivaScope, a reflectance confocal microscopy system for non-invasive skin imaging. It is the closest direct competitor to Enspectra's VIO system, as both aim to provide non-invasive cellular-level visualization of skin at the point of care.
  • Michelson Diagnostics (VivoSight): Michelson Diagnostics offers the VivoSight optical coherence tomography + confocal system for dermatology imaging. It competes directly with Enspectra in non-invasive skin imaging for lesion evaluation and shares the same enterprise dermatology customer base.
  • MetaOptima Technology (DermEngine): MetaOptima's DermEngine is an AI-powered dermatoscopy and tele-dermatology platform used by dermatologists for lesion tracking and AI-assisted assessment. It directly overlaps with Enspectra's AI-powered skin health assessment value proposition and target buyer.

Broad incumbents

  • Canfield Scientific: Canfield Scientific is the leading dermatology imaging vendor (VECTRA, IntelliStudio, VISIA) used by dermatologists and plastic surgeons for total body photography and lesion documentation. It is a broad incumbent in dermatology imaging workflows that Enspectra must integrate alongside or displace.
  • FotoFinder Systems: FotoFinder provides AI-assisted total body dermatoscopy and mole mapping systems widely used by dermatology practices globally. As a broad incumbent in dermatology imaging with AI, it represents the established workflow that Enspectra's point-of-care cellular imaging would complement or compete with.
  • Verily Life Sciences (Alphabet): Verily, an Alphabet health-tech company, has invested in dermatology AI and clinical research tools through partnerships and internal programs. As a broad incumbent with deep capital and data resources, it represents a well-capitalized competitive threat in AI dermatology.
  • STRATA Skin Sciences (formerly Mela Sciences): STRATA Skin Sciences markets dermatology imaging and diagnostic systems to dermatology practices. As a public dermatology imaging incumbent, it represents an established commercial channel and a potential acquirer or competitor for Enspectra's VIO technology.
  • 3Gen (DermLite): DermLite is a market-leading manufacturer of handheld dermatoscopes used in nearly every dermatology practice. It is a broad incumbent in the point-of-care skin imaging workflow that Enspectra is targeting with its VIO handheld form factor.

Emerging players

  • Skin Analytics: Skin Analytics is an emerging AI dermatology company (DERM) with regulatory clearances for autonomous skin cancer triage in the UK and EU. It competes in the same AI dermatology triage market as Enspectra but is currently focused on teledermatology and primary care pathways.
  • SkinVision: SkinVision offers a smartphone-based AI app for skin lesion risk assessment with regulatory clearances in Europe. It is an emerging player in AI dermatology triage and overlaps with Enspectra's thesis that non-invasive AI tools can reduce unnecessary biopsies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Enspectra Health social profiles

Digital presence

Enspectra Health compliance and trust

Trust signal

Compliance1 record

Enspectra Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enspectra Health leadership team

Management profile

Number of profiles

Profiles2 records

Enspectra Health funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enspectra Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enspectra Health

What does Enspectra Health do?

Enspectra Health develops and sells the VIO™ imaging system, a handheld medical device that combines multiphoton laser scanning with reflectance confocal microscopy to deliver non-invasive, real-time high-resolution digital images of live skin cells. The device is FDA-cleared and accompanied by AI-powered analysis that enables dermatologists to perform "virtual biopsies" for evaluating conditions such as nonmelanoma skin cancers without surgical incisions.

Is Enspectra Health a public or private company?

Enspectra Health is a private company. It is classified as venture growth investor backed and is currently operating.

When was Enspectra Health founded?

Enspectra Health was founded in 2014. It employs 1 to 10 people.

Where is Enspectra Health based?

Enspectra Health is headquartered in Mountain View, United States, in the North America region.

How does Enspectra Health make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are software/Subscription Services and service and Support.

Who are Enspectra Health's main competitors?

Direct peers on record are Caliber Imaging & Diagnostics (VivaScope), Michelson Diagnostics (VivoSight) and MetaOptima Technology (DermEngine). Broad incumbents are Canfield Scientific, FotoFinder Systems, Verily Life Sciences (Alphabet), STRATA Skin Sciences (formerly Mela Sciences) and 3Gen (DermLite). Emerging players are Skin Analytics and SkinVision.

Does Enspectra Health have an API?

No public API is recorded for Enspectra Health.

What industry is Enspectra Health in?

Enspectra Health's product category is Dermatology medical imaging devices. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TechCrunchBuilding venture-backable companies in heavily regulated spacesStartup Battlefield editor Isabelle Johannessen interviewed founders Gabriel Sanchez of Enspectra Health and Tom Harries of Earth Funeral regarding the challenges of operating in heavily regulated industries. The discussion highlights how Enspectra navigated a decade-long FDA clearance process for its dermatology device, while Earth Funeral overcame legislative hurdles to expand its human-to-soil transformation service beyond its initial state. Both cases illustrate that regulatory compliance requires careful planning but can coexist with innovation.TechCrunchThese startups are building innovations that make life (and death) betterGabriel Sanchez of Enspectra Health and Tom Harries of Earth Funeral discussed the challenges of building innovations in heavily regulated industries on the Build Mode podcast. They detailed their respective journeys, including Enspectra's decade-long FDA approval process for a skin imaging device and Earth Funeral's navigation of state-by-state regulations for human composting services. The discussion provided tactical advice on iterating during regulatory waits and raising venture capital in taboo sectors.PR NewswireStudy Published in JAMA Dermatology Validates Enspectra Health's Cross-Modal Imaging System for Noninvasive Visualization of Histologic Skin FeaturesEnspectra Health announced publication of pivotal clinical trial results in JAMA Dermatology demonstrating their handheld cross-modal imaging system (VIO) enables physicians to accurately identify histologic skin features noninvasively. The VISTA Trial, conducted at multiple U.S. dermatology centers with 65 participants, showed physicians achieved 96.4% accuracy for primary histologic features and 98.5% accuracy for secondary features. The system has received FDA clearance and is positioned to assist clinical decision-making without replacing traditional biopsy.ThedermdigestStudy: Enspectra Health’s Cross-modal Technology Delivers Histological Insights NoninvasivelyEnspectra Health's FDA-cleared cross-modal imaging technology provides real-time, non-invasive visualization of skin cellular structure. A study in Scientific Reports evaluated the system with healthy participants aged 9–81, showing histological details analogous to biopsied tissue, including dermal elastosis and basal cell carcinoma features.ThedermdigestFDA Awards Breakthrough Device Designation to Enspectra Health’s AI Platform for Classifying Non-melanoma Skin CancersThe FDA granted Breakthrough Device Designation to Enspectra Health's AI-powered VIO Skin Platform for classifying lesions suspicious for basal cell and squamous cell carcinoma in high-risk populations. The platform integrates FDA-cleared VIO technology with VIO.ai NMSC software for lesion classification. The designation aims to expedite development and provide timely access to the device.YahooEnspectra receives breakthrough status for AI-powered skin imaging platformEnspectra Health received FDA breakthrough device designation for its AI-powered VIO Skin Platform, which evaluates lesions for basal and squamous cell carcinoma in high-risk patients. The designation could expedite development and review, and the company's VIO System already has FDA 510(k) clearance.TmcnetEnspectra Health Receives FDA Breakthrough Device Designation for AI-powered Imaging Platform Targeting Skin CancerThe FDA granted Breakthrough Device Designation to Enspectra Health's AI-powered VIO Skin Platform for evaluating lesions suspicious of basal cell carcinoma and squamous cell carcinoma. The platform integrates FDA-cleared VIO technology with VIO.ai NMSC software for lesion classification. The designation aims to expedite development and provide timely access to the device.ThedermdigestFDA Clears Enspectra’s VIO‎ System for Biopsy-free Skin ImagingThe FDA granted 510(k) marketing clearance to Enspectra Health's VIO System, a portable handheld device combining reflectance confocal and multiphoton microscopy for skin imaging. The system was evaluated in the VISTA US Pivotal Study, where physicians identified skin features with over 90% average accuracy. Enspectra plans to pursue additional indications and advance its AI/ML clinical decision support algorithms.PR NewswireEnspectra Health Announces US FDA Clearance of VIO‎™ System, First of Its Kind Technology to Visualize Skin Cellular Structures in Real-TimeEnspectra Health received US FDA 510(k) clearance for its VIO System, the first multiphoton imaging modality cleared by the FDA. The handheld device combines reflectance confocal and multiphoton microscopy to provide cellular-resolution cross-sectional skin imaging in seconds. The company plans to pursue additional indications and advance its AI/ML clinical decision support algorithms.ThedermdigestDiagnosing Melanocytic TumorsDr. Jeffrey North discussed diagnostic challenges in melanocytic tumors at the 2022 Hawaii Dermpath Conference, highlighting the use of immunostains and next-generation sequencing to distinguish between benign nevi and malignant melanomas. The article emphasizes risk stratification to determine when expensive molecular testing is clinically necessary based on the potential for tumor spread. Dr. North disclosed his consulting relationships with Kiniksa Pharmaceuticals, Advinow Medical, and Enspectra.